ArticleAntibiotics (Basel, Switzerland)2019
Disulfiram (Tetraethylthiuram Disulfide) in the Treatment of Lyme Disease and Babesiosis: Report of Experience in Three Cases.
Article in Antibiotics (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03891667 (Disulfiram), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Disulfiram ("Antabuse"): A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease
Who cites it
24 citing papers in PubMed, 37 citations in OpenAlex.
- Off-label and repurposed use of disulfiram beyond alcohol dependence: A systematic review of clinical and preclinical evidence.iScience · 2026Article
- High-throughput LacZ/CPRG assay for identifying Gram-negative envelope-targeting antibiotics.Frontiers in microbiology · 2026Article
- Development of Low-Dose Disulfiram Rectal Suppository Intended for Application in Post-Treatment Lyme Disease Syndrome.Pharmaceutics · 2025Article
- A pilot study of disulfiram for individuals with persistent symptoms despite prior antibiotic treatment for Lyme disease.Frontiers in medicine · 2025Article
- Article
- Article
- The Use of Natural Bioactive Nutraceuticals in the Management of Tick-Borne Illnesses.Microorganisms · 2023Review
- Disulfiram: Mechanisms, Applications, and Challenges.Antibiotics (Basel, Switzerland) · 2023Review
- Disulfiram-Mitigating Unintended Effects.Antibiotics (Basel, Switzerland) · 2023Review
- Effect of Disulfiram on the Reproductive Capacity of Female Mice.International journal of molecular sciences · 2023Article
- Case report: Substantial improvement of autism spectrum disorder in a child with learning disabilities in conjunction with treatment for poly-microbial vector borne infections.Frontiers in psychiatry · 2023Article
- Synthesis and Biological Activity of Unsymmetrical Monoterpenylhetaryl Disulfides.Molecules (Basel, Switzerland) · 2022Article
- Efficacy of Short-Term High Dose Pulsed Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-Infections: A Report of Three Cases and Literature Review.Antibiotics (Basel, Switzerland) · 2022Article
- Disulfiram: A Repurposed Drug in Preclinical and Clinical Development for the Treatment of Infectious Diseases.Anti-infective agents · 2022Article
- Review
- Echis carinatus snake venom metalloprotease-induced toxicities in mice: Therapeutic intervention by a repurposed drug, Tetraethyl thiuram disulfide (Disulfiram).PLoS neglected tropical diseases · 2021Article
- "Repurposing" Disulfiram in the Treatment of Lyme Disease and Babesiosis: Retrospective Review of First 3 Years' Experience in One Medical Practice.Antibiotics (Basel, Switzerland) · 2020Article
- Efficacy of Double-Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-infections: A Report of Three Cases and Retrospective Chart Review.Antibiotics (Basel, Switzerland) · 2020Article
- Repurposing Disulfiram (Tetraethylthiuram Disulfide) as a Potential Drug Candidate againstAntibiotics (Basel, Switzerland) · 2020Article
- Evaluation of Disulfiram Drug Combinations and Identification of Other More Effective Combinations against Stationary PhaseAntibiotics (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Three patients, each of whom had required intensive open-ended antimicrobial therapy for control of the symptoms of chronic relapsing neurological Lyme disease and relapsing babesiosis, were able to discontinue treatment and remain clinically well for periods of observation of 6-23 months following the completion of a finite course of treatment solely with disulfiram. One patient relapsed at six months and is being re-treated with disulfiram.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.